TIDMRGT 
 
17 February 2011 
ReGen Therapeutics Plc 
(the "Company") 
 
                            Result of Court Hearing 
 
 
Further  to the announcement made on 12 January 2011, the Company announces that 
at  the High Court hearing that took place on 16 February 2011, approval for the 
reduction of capital was granted. 
 
Following  this approval,  the placing  of 300,000,000 new  ordinary shares (the 
"Placing  Shares") of 0.01 pence  in the Company  at 0.5 pence per share raising 
 GBP1,500,000 before expenses, has become unconditional. 
 
The  Placing Shares will rank  pari passu with the  Company's existing shares in 
all respects. Application has been made for the Placing Shares to be admitted to 
trading on AIM and dealings in these shares will commence on 18 February 2011. 
 
Following  the placing,  the issued  share capital  of the Company will comprise 
389,446,548 ordinary shares of 0.01 pence each. 
 
 
 
Enquiries: 
 
 ReGen Therapeutics Plc               +44 20 7153 4920 
 Percy Lomax 
 
 
 Cairn Financial Advisers LLP         +44 20 7148 7900 
 Nominated Adviser 
 Liam Murray / Avi Robinson 
 
 
 Alexander David Securities Limited   +44 20 7448 9820 
 Broker 
 David Scott / Nick Bealer 
 
 
 
 
 
 
 
 
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: ReGen Therapeutics Plc via Thomson Reuters ONE 
 
[HUG#1490142]
Argent Biopharma (LSE:RGT)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Argent Biopharma.
Argent Biopharma (LSE:RGT)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Argent Biopharma.